Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial

This study is aim to compare the clinical effectiveness between the two most prominent dry eye disease (DED)-specific eye drops, 0.05% cyclosporine (CN) and 3% diquafosol (DQ). This is a multi-centered, randomized, masked, prospective clinical study. A total of 153 DED patients were randomly allocat...

Full description

Saved in:
Bibliographic Details
Published in:BMC ophthalmology 2019-06, Vol.19 (1), p.131-9
Main Authors: Park, Chang Hyun, Lee, Hyung Keun, Kim, Mee Kum, Kim, Eun Chul, Kim, Jae Yong, Kim, Tae-Im, Kim, Hong Kyun, Song, Jong Suk, Yoon, Kyung Chul, Lee, Do Hyung, Chung, Tae-Young, Choi, Chul Young, Kim, Hyun Seung
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Bioavailability
Clinical trials
Comparative analysis
Conjunctiva - pathology
Cornea
Cyclosporine
Cyclosporine - therapeutic use
Cyclosporins
Diquafosol
Drug therapy
Dry eye disease
Dry eye syndromes
Dry Eye Syndromes - drug therapy
Evidence-based medicine
Eye diseases
Female
Humans
Immunosuppressive Agents - therapeutic use
Lubricant Eye Drops - therapeutic use
Male
Middle Aged
Nanoemulsions
Ocular surface disease index
Older people
Ophthalmic agents
Ophthalmic Solutions - therapeutic use
Ophthalmology
Patient compliance
Patients
Pharmaceuticals
Polyphosphates - therapeutic use
Prescription drugs
Prospective Studies
Schirmer’s test
Statistical analysis
Tear break-up time
Tears - physiology
Uracil Nucleotides - therapeutic use
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study is aim to compare the clinical effectiveness between the two most prominent dry eye disease (DED)-specific eye drops, 0.05% cyclosporine (CN) and 3% diquafosol (DQ). This is a multi-centered, randomized, masked, prospective clinical study. A total of 153 DED patients were randomly allocated to use CN twice per day or DQ six times daily. Cornea and conjunctival staining scores (NEI scale), tear break-up time (TBUT), Schirmer test scores, and ocular surface disease index (OSDI) score were measured at baseline, 4 and 12 weeks after treatment. At 12 weeks after treatment, NEI scaled scores were significantly reduced from the baseline by - 6.60 for CN and - 6.63 for DQ group (all P 
ISSN:1471-2415
1471-2415
DOI:10.1186/s12886-019-1136-8